{"product_id":"nutritional-management-of-renal-disease-hardback-9780123919342","title":"Nutritional Management of Renal Disease (Hardback) 9780123919342","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eNutritional Management of Renal Disease\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eJoel D. Kopple (Edited by), Shaul G Massry (Edited by), Kamyar Kalantar-Zadeh (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780123919342\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 29 January 2013\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e816 pages\u003cbr\u003e27.6 x 21.5 x 4.1 cm, 2.44 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\"This is a useful tool for nephrologists, especially in the clinical setting. The easy readability and suggested applications will also attract medical students, internists, renal dietitians, nurse practitioners, and physician assistants…Nutrition with its emerging importance at the cellular level is sometimes overlooked in training medical students. This book provides ready access to both the science and clinical application needed to treat the CKD population.\" Rating: 3 Stars--\u003cb\u003eDoody.com, February 28, 2014\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\"The Third Edition of this classic translational text offers in-depth reviews of the metabolic and nutritional disorders prevalent in patients with renal disease.\"--\u003cb\u003eDoody.com, April 24, 2013\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\"This edition reflects changes in the field, such as the increased evidence on the importance of inflammatory, oxidative, and carbonyl stress, and the greater prevalence and severity of obesity and its clinical consequences; therapeutic strategies for obesity treatment in regard to chronic kidney disease prevention and treatment; the nutritional management of people receiving chronic renal replacement therapy; and methods for slowing the progression of chronic renal disease...\"--\u003cb\u003eReference and Research Book News, February 2013\u003c\/b\u003e\u003c\/p\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eThis translational text offers in-depth reviews of the metabolic and nutritional disorders that are prevalent in patients with renal disease. Chapter topics address the growing epidemic of obesity and metabolic syndrome. Each chapter integrates basic and clinical approaches, from cell biology and genetics to diagnosis, patient management and treatment. Chapters in sections 4-7 include new illustrative case reports, and all chapters emphasize key concepts with chapter-ending summaries. New features also include the latest National Kidney Foundation Clinical Practice Guidelines on Nutrition in Chronic Renal Failure, the most recent scientific discoveries and the latest techniques for assessing nutritional status in renal disease, and literature reviews on patients who receive continuous veno-venous hemofiltration with or without dialysis. \u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eChapter 1. The Influence of Kidney Disease on Protein and Amino Acid Metabolism\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eCKD Interrupts the Components of Protein Metabolism\u003c\/p\u003e \u003cp\u003eDefining Muscle Wasting\u003c\/p\u003e \u003cp\u003eMechanisms of Muscle Wasting\u003c\/p\u003e \u003cp\u003eThe Ubiquitin-Proteasome System\u003c\/p\u003e \u003cp\u003eSynergism of Proteolytic Pathways Causes Muscle Wasting in CKD\u003c\/p\u003e \u003cp\u003eProteolytic Activities Present in Muscles of Patients\u003c\/p\u003e \u003cp\u003eFactors Triggering Muscle Wasting in CKD and Other Catabolic States\u003c\/p\u003e \u003cp\u003eMyostatin and the Regulation of Muscle Protein Wasting\u003c\/p\u003e \u003cp\u003eMyostatin in Muscle Increases in Catabolic Conditions\u003c\/p\u003e \u003cp\u003eBeneficial Responses from Blocking Myostatin in Models of Muscle Catabolism\u003c\/p\u003e \u003cp\u003eBlocking Myostatin can Suppress CKD-Induced Muscle Wasting\u003c\/p\u003e \u003cp\u003eCKD Changes the Concentrations of Certain Amino Acids\u003c\/p\u003e \u003cp\u003eLinks Between Amino Acid and Protein Metabolism\u003c\/p\u003e \u003cp\u003eConclusion\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 2. Carbohydrate Metabolism in Kidney Disease and Kidney Failure\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eInsulin Resistance\u003c\/p\u003e \u003cp\u003eInsulin Secretion\u003c\/p\u003e \u003cp\u003eInsulin Clearance\u003c\/p\u003e \u003cp\u003eHypoglycemia\u003c\/p\u003e \u003cp\u003eCarbohydrate Metabolism in Patients with Renal Replacement Therapy\u003c\/p\u003e \u003cp\u003eTreatment of Diabetes Mellitus in Diabetics with CKD\u003c\/p\u003e \u003cp\u003eDrug Management in Diabetics with CKD (Figure 2.1)\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 3. Altered Lipid Metabolism and Serum Lipids in Kidney Disease and Kidney Failure\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003ePlasma Lipid and Lipoprotein Profile in CKD\/ESRD Patients\u003c\/p\u003e \u003cp\u003eThe Nature and Mechanisms of CKD-Induced Lipid Abnormalities\u003c\/p\u003e \u003cp\u003eThe Nature and Mechanisms of Adverse Effects of Lipid Disorders in CKD\u003c\/p\u003e \u003cp\u003eTreatment of CKD-Associated Dyslipidemia\u003c\/p\u003e \u003cp\u003ePotential Adverse Effects of Statins\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 4. Uremic Toxicity\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eUremic Symptoms and Signs\u003c\/p\u003e \u003cp\u003eToxic Effects of Uremic Plasma or Serum\u003c\/p\u003e \u003cp\u003eDefinition of a Uremic Toxin\u003c\/p\u003e \u003cp\u003eImpact of Dialysis Treatment on Uremic Toxicity\u003c\/p\u003e \u003cp\u003eToxicity of Inorganic Substances in Uremia\u003c\/p\u003e \u003cp\u003eFree Water-Soluble Low-Molecular-Weight Solutes\u003c\/p\u003e \u003cp\u003eProtein-Bound Solutes\u003c\/p\u003e \u003cp\u003eMiddle Molecules\u003c\/p\u003e \u003cp\u003eGeneral Conclusions\u003c\/p\u003e \u003cp\u003eAcknowledgement\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 5. Inflammation in Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eGeneral Considerations\u003c\/p\u003e \u003cp\u003eMultifactorial Causes of Inflammation in Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eInflammation as a Cause of Protein-Energy Wasting\u003c\/p\u003e \u003cp\u003eInflammation as a Catalyst of Other Risk Factors\u003c\/p\u003e \u003cp\u003eOther Consequences of Inflammation\u003c\/p\u003e \u003cp\u003eMonitoring Inflammation\u003c\/p\u003e \u003cp\u003eTreatment of Inflammation in Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 6. Catalytic (Labile) Iron in Kidney Disease\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eDefinition of Catalytic (Labile) Iron and its Importance in Tissue Injury\u003c\/p\u003e \u003cp\u003eRole of Catalytic Iron in Acute Kidney Injury\u003c\/p\u003e \u003cp\u003eGentamicin-Induced Mobilization of Iron From Renal Cortical Mitochondria\u003c\/p\u003e \u003cp\u003eEvidence Suggesting a Role for Iron in Gentamicin-Induced Acute Renal Failure in Rats\u003c\/p\u003e \u003cp\u003eCatalytic Iron in Chronic Kidney Disease (Table 6.3)\u003c\/p\u003e \u003cp\u003eCatalytic Iron in Diabetic Nephropathy\u003c\/p\u003e \u003cp\u003eCatalytic Iron in Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eConcluding Comments\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 7. Carbonyl Stress in Uremia\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eIncreased Age and other Protein Modifications\u003c\/p\u003e \u003cp\u003eCarbonyl Stress\u003c\/p\u003e \u003cp\u003eClinical Consequences of Carbonyl Stress\u003c\/p\u003e \u003cp\u003eNutrition and Carbonyl Stress\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 8. Effect of Acidemia and Alkalemia on Nutrition and Metabolism\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eAcute Responses to Acidosis and Alkalosis\u003c\/p\u003e \u003cp\u003eComparing Effects of Acidemia to those of Starvation\u003c\/p\u003e \u003cp\u003eEndocrine Responses to Acidemia\u003c\/p\u003e \u003cp\u003eCalcium Metabolism\u003c\/p\u003e \u003cp\u003eProtein Malnutrition\u003c\/p\u003e \u003cp\u003eMetabolic Acidemia Stimulates the Ubiquitin\/Proteasome Proteolytic Pathway\u003c\/p\u003e \u003cp\u003eClinical Implications of Acidemia for Protein Nutrition\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 9. Prevention and Management of Cardiovascular Disease in Kidney Disease and Kidney Failure\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eCardiovascular Risk Factors\u003c\/p\u003e \u003cp\u003eManagement of CVD\u003c\/p\u003e \u003cp\u003eConclusion\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 10. Assessment of Protein and Energy Nutritional Status\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eDefinition of Protein and Energy Wasting\u003c\/p\u003e \u003cp\u003eAssessment of Protein Mass\u003c\/p\u003e \u003cp\u003eAssessment of Protein and Energy Homeostasis\u003c\/p\u003e \u003cp\u003eSummary and Recommendations\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 11. Causes of Protein-Energy Wasting in Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eCauses of Pew in CKD\u003c\/p\u003e \u003cp\u003ePathophysiology of Pew in CKD\u003c\/p\u003e \u003cp\u003eEndocrine and Hormonal Disorders\u003c\/p\u003e \u003cp\u003eEffect of Volume Overload\u003c\/p\u003e \u003cp\u003eContribution of Co-Morbidities\u003c\/p\u003e \u003cp\u003eAltered Protein Kinetics in CKD\u003c\/p\u003e \u003cp\u003eNutrient Loss During Dialysis\u003c\/p\u003e \u003cp\u003eInflammation: Agent Provocateur of Pew\u003c\/p\u003e \u003cp\u003eRole of Metabolic Acidemia\u003c\/p\u003e \u003cp\u003eOxidative Stress: Other Key Pathways\u003c\/p\u003e \u003cp\u003eSummary and Conclusion\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 12. Protein-Energy Wasting as a Risk Factor of Morbidity and Mortality in Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003ePertinent Outcomes in Patients with CKD\u003c\/p\u003e \u003cp\u003eAssociation of Measures of Nutrition with Outcomes\u003c\/p\u003e \u003cp\u003eNutrient Intake and Outcomes\u003c\/p\u003e \u003cp\u003eBody Size, Body Composition and Outcomes\u003c\/p\u003e \u003cp\u003eLaboratory Measures and Outcome\u003c\/p\u003e \u003cp\u003eNutritional Scoring Systems and Outcomes\u003c\/p\u003e \u003cp\u003eNutritional Interventions and Outcomes\u003c\/p\u003e \u003cp\u003eConclusions\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 13. Effect of Nutritional Status and Changes in Protein Intake on Renal Function\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eRole of Specific AA\u003c\/p\u003e \u003cp\u003eFactors Mediating the Renal Response to Protein and Amino Acids\u003c\/p\u003e \u003cp\u003eHumoral Mediators\u003c\/p\u003e \u003cp\u003eLocal Mediators\u003c\/p\u003e \u003cp\u003eIntrinsic Renal Mechanisms\u003c\/p\u003e \u003cp\u003eEffects of Nutritional Status or Protein Deprivation on Renal Function\u003c\/p\u003e \u003cp\u003eLevels of Plasma Creatinine and Serum Urea Nitrogen in Patients with Protein-Energy Malnutrition\u003c\/p\u003e \u003cp\u003eConcentration and Dilution of the Urine in Patients with Protein-Energy Malnutrition\u003c\/p\u003e \u003cp\u003eAcid Excretion and Acid-Base Balance in Patients with Calorie-Protein Malnutrition\u003c\/p\u003e \u003cp\u003eEffects of Chronic Protein-Energy Malnutrition on Renal Sodium Excretion\u003c\/p\u003e \u003cp\u003eEffects of Maternal Nutrition on Renal Development\u003c\/p\u003e \u003cp\u003eProtein Energy Wasting in Advanced Renal Disease\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 14. Low Protein, Amino Acid and Ketoacid Diets to Slow the Progression of Chronic Kidney Disease and Improve Metabolic Control of Uremia\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eAssessing the Progression of Chronic Renal Insufficiency\u003c\/p\u003e \u003cp\u003eProtein Intake and Chronic Renal Insufficiency: Experimental Data\u003c\/p\u003e \u003cp\u003eDietary Protein Intake: Clinical Studies\u003c\/p\u003e \u003cp\u003eClinical Evidence of the Effects of Low Protein Diets\u003c\/p\u003e \u003cp\u003eConclusion\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 15. Reducing Tryptophan Metabolites to Reduce Progression in Chronic Kidney Failure\u003c\/p\u003e \u003cp\u003eSearch for Uremic Toxins\u003c\/p\u003e \u003cp\u003eMetabolism of Indoxyl Sulfate, a Tryptophan Metabolite\u003c\/p\u003e \u003cp\u003eProtein Metabolite Theory as a Mechanism of CKD Progression\u003c\/p\u003e \u003cp\u003eIndoxyl Sulfate Induces Reactive Oxygen Species (ROS) in the Kidney\u003c\/p\u003e \u003cp\u003eRole of Organic Anion Transporters in Nephrotoxicity of Indoxyl Sulfate\u003c\/p\u003e \u003cp\u003eIndoxyl Sulfate Reduces Klotho and Induces Senescence in the Kidney\u003c\/p\u003e \u003cp\u003eVascular Toxicity of Indoxyl Sulfate\u003c\/p\u003e \u003cp\u003eClinical Effects of AST-120\u003c\/p\u003e \u003cp\u003eConclusion\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 16. Altering Serum Lipids to Reduce Progression of Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eKidney Disease and Dyslipidemia\u003c\/p\u003e \u003cp\u003eLipid Lowering and Pleiotropic Effects of Statins\u003c\/p\u003e \u003cp\u003eStatins in Experimental Kidney Disease\u003c\/p\u003e \u003cp\u003eEffects of Dyslipidemia and Statins on the Progression of Kidney Disease in Human Subjects\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 17. Disorders of Phosphorus Homeostasis: Emerging Targets for Slowing Progression of Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eRole of Dietary Phosphorus Intake in Disturbances of Mineral Metabolism in CKD\u003c\/p\u003e \u003cp\u003eDisorders of Phosphorus Homeostasis and Kidney Disease Progression\u003c\/p\u003e \u003cp\u003eDietary Phosphorus Restriction in CKD: Practical Considerations Moving Forward\u003c\/p\u003e \u003cp\u003eConclusions\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 18. Alkalinization to Retard Progression of Chronic Kidney Failure\u003c\/p\u003e \u003cp\u003eEpidemiology of Metabolic Acidosis in Kidney Disease\u003c\/p\u003e \u003cp\u003eMechanism of Acidosis in CKD\u003c\/p\u003e \u003cp\u003eAnimal Models of Kidney Damage With Acidosis\u003c\/p\u003e \u003cp\u003eAnimal Models of Treatment\u003c\/p\u003e \u003cp\u003eObservational Studies in Humans\u003c\/p\u003e \u003cp\u003eRecommendations\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 19. Calcium, Phosphate, PTH, Vitamin D and FGF-23 in Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eCalcium Metabolism\u003c\/p\u003e \u003cp\u003eVitamin D\u003c\/p\u003e \u003cp\u003ePhosphate Metabolism\u003c\/p\u003e \u003cp\u003eParathyroid Hormone\u003c\/p\u003e \u003cp\u003eFibroblast Growth Factor 23 (FGF-23)\u003c\/p\u003e \u003cp\u003eAlterations in Mineral Metabolism in Ckd\u003c\/p\u003e \u003cp\u003ePhosphate and Cardiovascular Disease (CVD)\u003c\/p\u003e \u003cp\u003ePhosphate and Vascular Calcifications\u003c\/p\u003e \u003cp\u003eControl of Serum Phosphate in CKD\u003c\/p\u003e \u003cp\u003eDietary Phosphorus Restriction\u003c\/p\u003e \u003cp\u003eInorganic Phosphorus and Food Additives\u003c\/p\u003e \u003cp\u003eDietary Phosphorus, Protein Intake and Phosphorus-Protein Ratio\u003c\/p\u003e \u003cp\u003ePhosphorus Removal With Dialysis\u003c\/p\u003e \u003cp\u003ePhosphate Binders\u003c\/p\u003e \u003cp\u003eTherapy With Vitamin D Sterols\u003c\/p\u003e \u003cp\u003eCalcimimetics\u003c\/p\u003e \u003cp\u003eConclusion\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 20. Phosphate Metabolism and Fibroblast Growth Factor 23 in Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003ePhosphate Metabolism in Health\u003c\/p\u003e \u003cp\u003ePhosphate Metabolism Across the Spectrum of CKD\u003c\/p\u003e \u003cp\u003eThe Role of Phosphate and FGF-23 Excess in the Pathophysiology of CKD Outcomes\u003c\/p\u003e \u003cp\u003eTherapeutic Approaches to Lowering Phosphate and FGF-23 Excess\u003c\/p\u003e \u003cp\u003eImpact of Dietary Phosphate on Phosphate\/FGF-23 Excess\u003c\/p\u003e \u003cp\u003eQuestions and Controversies\u003c\/p\u003e \u003cp\u003eConclusions\u003c\/p\u003e \u003cp\u003eAcknowledgments\u003c\/p\u003e \u003cp\u003eDisclosures\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 21. Vitamin D in Kidney Disease\u003c\/p\u003e \u003cp\u003eNormal Vitamin D Metabolism\u003c\/p\u003e \u003cp\u003ePrevalence and Etiology of Deficiency in The Vitamin D Axis in CKD\u003c\/p\u003e \u003cp\u003eImplications\u003c\/p\u003e \u003cp\u003eInterventions\u003c\/p\u003e \u003cp\u003eOther Compounds\u003c\/p\u003e \u003cp\u003eTherapeutic Considerations\u003c\/p\u003e \u003cp\u003eSummary\u003c\/p\u003e \u003cp\u003eAcknowledgement\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 22. Nutritional Management of Water, Sodium, Potassium, Chloride, and Magnesium in Kidney Disease and Kidney Failure\u003c\/p\u003e \u003cp\u003eSodium and Chloride\u003c\/p\u003e \u003cp\u003eWater\u003c\/p\u003e \u003cp\u003ePotassium\u003c\/p\u003e \u003cp\u003eMagnesium\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 23. Trace Elements, Toxic Metals, and Metalloids in Kidney Disease\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eAlterations in Essential Trace Elements in Patients With Kidney Disease\u003c\/p\u003e \u003cp\u003eAlterations in Nonessential Trace Elements, Metals, and Metalloids in Patients With Kidney Disease\u003c\/p\u003e \u003cp\u003eTrace Element Abnormalities in Renal-Specific Syndromes\u003c\/p\u003e \u003cp\u003eDiagnostic and Therapeutic Approaches\u003c\/p\u003e \u003cp\u003eConclusions\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 24. Vitamin Metabolism and Requirements in Renal Disease and Renal Failure\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eStructure and Physiological Role of Vitamins\u003c\/p\u003e \u003cp\u003eVitamin Intake in Chronic Renal Disease\u003c\/p\u003e \u003cp\u003eVitamins Status in Chronic Renal Disease\u003c\/p\u003e \u003cp\u003eVitamins as Therapy for People with Kidney Disease\u003c\/p\u003e \u003cp\u003eRecommendations for Vitamin Supplementation and Vitamin Therapy in Renal Diseases\u003c\/p\u003e \u003cp\u003eConclusions\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 25. Nutrition and Anemia in End-stage Renal Disease\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eIron\u003c\/p\u003e \u003cp\u003eVitamin C\u003c\/p\u003e \u003cp\u003eVitamin D\u003c\/p\u003e \u003cp\u003eFolic Acid\u003c\/p\u003e \u003cp\u003eVitamin B6 (Pyridoxine)\u003c\/p\u003e \u003cp\u003eVitamin B12\u003c\/p\u003e \u003cp\u003eCarnitine\u003c\/p\u003e \u003cp\u003eGrowth Hormone and Insulin-Like Growth Factor-I (IGF-I)\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 26. Nutritional and Non-nutritional Management of the Nephrotic Syndrome\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eDietary Protein\u003c\/p\u003e \u003cp\u003eAlbumin Homeostasis in the Nephrotic Syndrome\u003c\/p\u003e \u003cp\u003eDietary Protein and Renal Injury\u003c\/p\u003e \u003cp\u003eEffects of the Nephrotic Syndrome on Solid Tissue Proteins\u003c\/p\u003e \u003cp\u003eDietary Proteins as Potential Allergens Responsible for Renal Disease\u003c\/p\u003e \u003cp\u003eDietary Fat\u003c\/p\u003e \u003cp\u003eThe Effect of Altered Glomerular Permselectivity on Lipid Metabolism\u003c\/p\u003e \u003cp\u003eCardiovascular Effects of Hyperlipidemia in the Nephrotic Syndrome\u003c\/p\u003e \u003cp\u003eThromboembolic Complications\u003c\/p\u003e \u003cp\u003eEffects of Lipids on Renal Disease\u003c\/p\u003e \u003cp\u003ePolyunsaturated Fatty Acids\u003c\/p\u003e \u003cp\u003eDerangements in Divalent Cation Metabolism in the Nephrotic Syndrome\u003c\/p\u003e \u003cp\u003eDerangements in Salt and Water Metabolism in the Nephrotic Syndrome (Volume Homeostasis)\u003c\/p\u003e \u003cp\u003eRecommendations for Nutritional and Non-Nutritional Treatment of the Nephrotic Syndrome\u003c\/p\u003e \u003cp\u003eAcknowledgements\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 27. Nutrition and Blood Pressure\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eObesity and Energy Intake\u003c\/p\u003e \u003cp\u003eIndividual Nutrients, Miscellaneous Substances and Blood Pressure\u003c\/p\u003e \u003cp\u003eNutritional Management Strategies for The Prevention or Treatment of Hypertension\u003c\/p\u003e \u003cp\u003eHealth Enhancing Diets and Lifestyles\u003c\/p\u003e \u003cp\u003eLong-Term Adherence and Blood Pressure Responses to Health Enhancing Lifestyles\u003c\/p\u003e \u003cp\u003eChallenges to Diet and Lifestyle Approaches for Preventing and Treating Hypertension\u003c\/p\u003e \u003cp\u003eConclusions and Recommendations\u003c\/p\u003e \u003cp\u003eKey Points\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 28. Effect of Obesity and the Metabolic Syndrome on Incident Kidney Disease and the Progression to Chronic Kidney Failure\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eDefinitions of Obesity\/Metabolic Syndrome\u003c\/p\u003e \u003cp\u003eObesity and Metabolic Syndrome as Risk Factors for Incident CKD\u003c\/p\u003e \u003cp\u003eObesity and Metabolic Syndrome as Risk Factors for Progression of CKD\u003c\/p\u003e \u003cp\u003ePathophysiology of Obesity on the Kidney\u003c\/p\u003e \u003cp\u003eEffect of Weight Loss Interventions on Kidney Disease\u003c\/p\u003e \u003cp\u003eConclusion\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 29. Nutritional and Metabolic Management of Obesity and the Metabolic Syndrome in the Patient with Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eObesity-Related Chronic Kidney Disease (CKD)\u003c\/p\u003e \u003cp\u003eObesity-Related Glomerulopathy\u003c\/p\u003e \u003cp\u003eMeasuring GFR\u003c\/p\u003e \u003cp\u003eMetabolic Syndrome\u003c\/p\u003e \u003cp\u003eTreatment of Obesity and Obesity-Related Kidney Disease\u003c\/p\u003e \u003cp\u003eBariatric Surgery (see also Chapter 28)\u003c\/p\u003e \u003cp\u003eMetabolic Syndrome\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 30. Bariatric Surgery and Renal Disease\u003c\/p\u003e \u003cp\u003eMagnitude of Problem\u003c\/p\u003e \u003cp\u003ePathogenesis of Obesity\u003c\/p\u003e \u003cp\u003eClinical Manifestations\u003c\/p\u003e \u003cp\u003eMedical Therapy\u003c\/p\u003e \u003cp\u003eRole of Bariatric Surgery in Treatment of Morbid Obesity\u003c\/p\u003e \u003cp\u003eSurgical Techniques of Bariatric Surgery (see Figure 30.1)\u003c\/p\u003e \u003cp\u003eOutcomes of Bariatric Surgery\u003c\/p\u003e \u003cp\u003eRenal Disease and Morbid Obesity\u003c\/p\u003e \u003cp\u003ePathogenesis of Renal Disease in Obesity\u003c\/p\u003e \u003cp\u003eRole of Bariatric Surgery in Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eRole of Bariatric Surgery in Transplant Candidates\u003c\/p\u003e \u003cp\u003eBariatric Surgery and Nephrolithiasis\u003c\/p\u003e \u003cp\u003eOther Renal Effects of Bariatric Surgery\u003c\/p\u003e \u003cp\u003eFuture Research\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 31. Nutritional and Metabolic Management of the Diabetic Patient with Chronic Kidney Disease and Chronic Renal Failure\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eGlucose\/Insulin Homeostasis\u003c\/p\u003e \u003cp\u003eValue of Glycemic Control, and its Determination in CKD\u003c\/p\u003e \u003cp\u003eHypoglycemia\u003c\/p\u003e \u003cp\u003eDiabetes\/Bone and Mineral Metabolism\u003c\/p\u003e \u003cp\u003eDietary Protein Intake and Diabetic Kidney Disease\u003c\/p\u003e \u003cp\u003eSalt Intake and Diabetic Kidney Disease\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 32. Nutritional Management of Maintenance Hemodialysis Patients\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eFactors Altering Nutrient Intake in Maintenance Hemodialysis Patients\u003c\/p\u003e \u003cp\u003eLoss of Nutrients During Maintenance Hemodialysis Treatment\u003c\/p\u003e \u003cp\u003eImportance of Pew and Diet as Patients Approach Esrd and Commence MHD\u003c\/p\u003e \u003cp\u003eAssessment of Nutritional Status in MHD Patients\u003c\/p\u003e \u003cp\u003eAcidemia and Protein Wasting\u003c\/p\u003e \u003cp\u003eGoals of Nutritional Management of MHD Patients\u003c\/p\u003e \u003cp\u003eDietary Nutrient Requirements (see Table 32.3)\u003c\/p\u003e \u003cp\u003eManagement of Pew in MHD Patients\u003c\/p\u003e \u003cp\u003eTreatment of Acute Catabolic Illness\u003c\/p\u003e \u003cp\u003eDaily or Long Duration Hemodialysis and Nutritional Status\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 33. Nutritional Management of End-Stage Renal Disease Patients Treated with Peritoneal Dialysis\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eType of Peritoneal Dialysis\u003c\/p\u003e \u003cp\u003ePeritoneal Dialysis Solutions\u003c\/p\u003e \u003cp\u003eSpecific Effects of Peritoneal Dialysis on Nutritional Status and Metabolism\u003c\/p\u003e \u003cp\u003eDietary Recommendations for ESRD Patients Undergoing Peritoneal Dialysis\u003c\/p\u003e \u003cp\u003eProtein-Energy Wasting in Peritoneal Dialysis Patients\u003c\/p\u003e \u003cp\u003eManagement of Protein-Energy Wasting in Patients Treated with Peritoneal Dialysis\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 34. Nutritional Management of Kidney Transplant Recipients\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eAnemia\u003c\/p\u003e \u003cp\u003eBone Disease\u003c\/p\u003e \u003cp\u003eDiabetes Mellitus\u003c\/p\u003e \u003cp\u003eDyslipidemia\u003c\/p\u003e \u003cp\u003eHypertension\u003c\/p\u003e \u003cp\u003eFood Safety\u003c\/p\u003e \u003cp\u003eHypophosphatemia\u003c\/p\u003e \u003cp\u003eOverweight\/Obesity\u003c\/p\u003e \u003cp\u003eMalnutrition\u003c\/p\u003e \u003cp\u003eProtein and Energy Requirements\u003c\/p\u003e \u003cp\u003eNutritional Management\u003c\/p\u003e \u003cp\u003ePretransplant Status and Posttransplant Outcome\u003c\/p\u003e \u003cp\u003eConclusion\u003c\/p\u003e \u003cp\u003eAcknowledgements\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 35. Nutritional Management of the Child with Kidney Disease\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eEtiology of Protein-Energy Wasting\u003c\/p\u003e \u003cp\u003eAssessment of Nutritional Status\u003c\/p\u003e \u003cp\u003eNutritional Requirements\u003c\/p\u003e \u003cp\u003eBone Mineral Metabolism\u003c\/p\u003e \u003cp\u003eAcid–Base and Electrolytes\u003c\/p\u003e \u003cp\u003eVitamins and Micronutrients\u003c\/p\u003e \u003cp\u003eNutrition Management\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 36. Nutritional Management of Acute Kidney Injury\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eMetabolic Environment of the Patient with AKI\u003c\/p\u003e \u003cp\u003eMetabolic Alterations Specifically Attributable to AKI\u003c\/p\u003e \u003cp\u003eMetabolic Interventions of Controlling Catabolism\u003c\/p\u003e \u003cp\u003eClinical Studies on Protein Catabolism in AKI\u003c\/p\u003e \u003cp\u003eAmino Acid\/Protein Requirements in Patients with AKI\u003c\/p\u003e \u003cp\u003eCarbohydrate Metabolism\u003c\/p\u003e \u003cp\u003eLipid Metabolism\u003c\/p\u003e \u003cp\u003eMicronutrients and the Antioxidant System in AKI\u003c\/p\u003e \u003cp\u003eElectrolytes\u003c\/p\u003e \u003cp\u003eMetabolic and Nutritional Factors and the Prevention and Therapy of AKI\u003c\/p\u003e \u003cp\u003eImpact of Renal Replacement Therapy (RRT) on Metabolism and Nutrient Balances\u003c\/p\u003e \u003cp\u003eThe Effect of Nutrition Status and Nutrient Supply on Prognosis\u003c\/p\u003e \u003cp\u003ePractice of Clinical Nutrition in Patients with AKI\u003c\/p\u003e \u003cp\u003eOral Nutrition in Patients with AKI\u003c\/p\u003e \u003cp\u003eNutritional Support in Patients with AKI\u003c\/p\u003e \u003cp\u003eEnteral Nutrition in AKI\u003c\/p\u003e \u003cp\u003eParenteral Nutrition in AKI\u003c\/p\u003e \u003cp\u003eComplications of Nutritional Support\u003c\/p\u003e \u003cp\u003eMonitoring of Nutrition Support in Patient with AKI\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 37. Nutritional Management of Patients Treated with Continuous Renal Replacement Therapy\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eModes of CRRT\u003c\/p\u003e \u003cp\u003eGeneric Effects of CRRT on Energy Metabolism\u003c\/p\u003e \u003cp\u003eSpecific Effects on Nutrient Balance\u003c\/p\u003e \u003cp\u003eRecommendations on Nutritional Therapy\u003c\/p\u003e \u003cp\u003eConclusion\u003c\/p\u003e \u003cp\u003eAcknowledgements\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 38. Anorexia and Appetite Stimulants in Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eGeneral Considerations\u003c\/p\u003e \u003cp\u003ePrevalence of Anorexia, Methods of Assessment and Clinical Implications\u003c\/p\u003e \u003cp\u003ePathogenesis of Anorexia in CKD\u003c\/p\u003e \u003cp\u003eTreatment of Anorexia in CKD\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 39. Oral and Enteral Supplements in Kidney Disease and Kidney Failure\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eOral and Enteral (Tube Feeding) Nutrition in CKD Patients\u003c\/p\u003e \u003cp\u003eOral and Enteral Nutrition for Patients with Nephrotic Syndrome\u003c\/p\u003e \u003cp\u003eOral and Enteral Nutrition in Chronic Dialysis Patients\u003c\/p\u003e \u003cp\u003eOral and Enteral Nutrition in Acute Kidney Injury\u003c\/p\u003e \u003cp\u003eConclusions\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 40. Intradialytic Parenteral Nutrition, Intraperitoneal Nutrition and Nutritional Hemodialysis\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eIntradialytic Parenteral Nutrition (IDPN)\u003c\/p\u003e \u003cp\u003eRandomized Prospective Controlled Trials of IDPN\u003c\/p\u003e \u003cp\u003eAdvantages and Disadvantages of IDPN\u003c\/p\u003e \u003cp\u003eIndications for IDPN\u003c\/p\u003e \u003cp\u003eIDPN in the United States\u003c\/p\u003e \u003cp\u003eNutritional Hemodialysis and Intraperitoneal Nutrition\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 41. Therapeutic Use of Growth Factors in Renal Disease\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eTreatment of Protein-Energy Wasting (PEW) in ESRD Patients\u003c\/p\u003e \u003cp\u003eTherapeutic Use of Growth Factors in Renal Disease\u003c\/p\u003e \u003cp\u003eGrowth Factors in the Management of Wasting in Renal Disease\u003c\/p\u003e \u003cp\u003eConclusion\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 42. Nutritional Prevention and Treatment of Kidney Stones\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003ePathophysiology of Kidney Stone Formation\u003c\/p\u003e \u003cp\u003eGeneral Dietary Effects on Kidney Stones\u003c\/p\u003e \u003cp\u003eEffect of Diet Based on Urinary Findings\u003c\/p\u003e \u003cp\u003eDietary Recommendations Based on Stone Type\u003c\/p\u003e \u003cp\u003eObesity and Kidney Stones\u003c\/p\u003e \u003cp\u003eMelamine Stones\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 43. Herbal Supplements in Patients with Kidney Disease\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eAcute Kidney Injury\u003c\/p\u003e \u003cp\u003eChronic Kidney Disease\u003c\/p\u003e \u003cp\u003eFive Herbals with Some Proven Efficacy\u003c\/p\u003e \u003cp\u003eTransplant\u003c\/p\u003e \u003cp\u003eClinical Implications\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 44. Drug–Nutrient Interactions in Renal Failure\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eEffect of Food Intake on Drug Absorption\u003c\/p\u003e \u003cp\u003eEffects of Nutrients on Drug Metabolism\u003c\/p\u003e \u003cp\u003eInteractions of Food Supplements with Drugs\u003c\/p\u003e \u003cp\u003eDrug-Induced Nutritional Deficiencies\u003c\/p\u003e \u003cp\u003eTaurine and ACE-Inhibitor Effects\u003c\/p\u003e \u003cp\u003eNutrient Interactions with Oral Anticoagulants\u003c\/p\u003e \u003cp\u003eInteractions of Calcineurin Inhibitors with Nutrients\u003c\/p\u003e \u003cp\u003eEnteral Tube Feeding and Oral Drug Administration\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 45. Exercise Training for Individuals with Advanced Chronic Kidney Disease\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eCharacteristics of Advanced CKD Patients\u003c\/p\u003e \u003cp\u003eValue of Exercise and Physical Activity in Advanced CKD\u003c\/p\u003e \u003cp\u003ePrinciples of Exercise Training\u003c\/p\u003e \u003cp\u003ePatient Assessment\u003c\/p\u003e \u003cp\u003eComponents of the Exercise Training Prescription\u003c\/p\u003e \u003cp\u003eExercise Training Program Design for Patients with Advanced CKD\u003c\/p\u003e \u003cp\u003eComponents of the Exercise Training Session\u003c\/p\u003e \u003cp\u003eRisks of Exercise in the Advanced CKD Patient\u003c\/p\u003e \u003cp\u003eUrgent Need for Development of Renal Rehabilitation Programs\u003c\/p\u003e \u003cp\u003eSummary\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eChapter 46. Motivating the Kidney Disease Patient to Nutrition Adherence and Other Healthy Lifestyle Activities\u003c\/p\u003e \u003cp\u003eIntroduction\u003c\/p\u003e \u003cp\u003eWhat is Motivational Interviewing?\u003c\/p\u003e \u003cp\u003eWhat isn’t Motivational Interviewing?\u003c\/p\u003e \u003cp\u003ePrinciples\u003c\/p\u003e \u003cp\u003eHandling Resistance\u003c\/p\u003e \u003cp\u003eEmpirical Support\u003c\/p\u003e \u003cp\u003eApplications in Kidney Disease Management\u003c\/p\u003e \u003cp\u003eLearning Motivational Interviewing\u003c\/p\u003e \u003cp\u003eDissemination of Motivational Interviewing\u003c\/p\u003e \u003cp\u003eFuture Research Directions in Kidney Disease Management\u003c\/p\u003e \u003cp\u003eConclusions\u003c\/p\u003e \u003cp\u003eReferences\u003c\/p\u003e \u003cp\u003eColor Plates\u003c\/p\u003e \u003cp\u003eIndex\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Food \u0026amp; beverage technology [\u003ca title=\"See our other books on Food \u0026amp; beverage technology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Food%20\u0026amp;%20beverage%20technology%20%5BTDCT%5D%22\"\u003eTDCT\u003c\/a\u003e], Pharmacology [\u003ca title=\"See our other books on Pharmacology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Pharmacology%20%5BMMG%5D%22\"\u003eMMG\u003c\/a\u003e], Renal medicine \u0026amp; nephrology [\u003ca title=\"See our other books on Renal medicine \u0026amp; nephrology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Renal%20medicine%20\u0026amp;%20nephrology%20%5BMJR%5D%22\"\u003eMJR\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Freshly Printed Books","offers":[{"title":"Default Title","offer_id":46648990236952,"sku":"9780123919342","price":76.59,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/products\/9780123919342_8a7cdc49-4abd-4c13-a1a4-70f41cd4463e.jpg?v=1694352185","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/nutritional-management-of-renal-disease-hardback-9780123919342","provider":"Freshly Printed Books","version":"1.0","type":"link"}